Allergy Therapeutics plc
AGY.LDrugs in Pipeline
15
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Ragweed MATA MPL
Type I Hypersensitivity
PQ Grass
Rhinitis, Allergic, Seasonal
PURETHAL Mites 50,000 AUeq/ml
House Dust Mite Allergy
Grass MATA MPL
Type I Hypersensitivity
PURETHAL Mites 6,667 AU/ml
Allergic Rhinitis
Grass MATA MPL (0.5ml) 5100SU
Seasonal Allergic Rhinitis
sublingual immunotherapy
Seasonal Rhinitis and/or Rhinoconjunctivitis
SUBLIVAC FIX Mite mixture
House Dust Mite Allergy
Ragweed MATAMPL
Type I Hypersensitivity
Tree MATA MPL - Therapeutic Regimen
Type I Hypersensitivity
RagweedMATAMPL
Type I Hypersensitivity
TreeMATA MPL
Type I Hypersensitivity
SUBLIVAC FIX phleum prat.
Allergic Rhinitis
Grass MATAMPL
Type I Hypersensitivity
Tree MATA MPL
Type I Hypersensitivity
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ragweed MATA MPL | Phase 3 | Type I Hypersensitivity | - | - |
PQ Grass | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
PURETHAL Mites 50,000 AUeq/ml | Phase 3 | House Dust Mite Allergy | - | - |
Grass MATA MPL | Phase 3 | Type I Hypersensitivity | - | - |
PURETHAL Mites 6,667 AU/ml | Phase 2 | Allergic Rhinitis | - | - |
Grass MATA MPL (0.5ml) 5100SU | Phase 2 | Seasonal Allergic Rhinitis | - | - |
sublingual immunotherapy | Phase 2 | Seasonal Rhinitis and/or Rhinoconjunctivitis | - | - |
SUBLIVAC FIX Mite mixture | Phase 2 | House Dust Mite Allergy | - | - |
Ragweed MATAMPL | Phase 2 | Type I Hypersensitivity | - | - |
Tree MATA MPL - Therapeutic Regimen | Phase 2 | Type I Hypersensitivity | - | - |
RagweedMATAMPL | Phase 2 | Type I Hypersensitivity | - | - |
TreeMATA MPL | Phase 2 | Type I Hypersensitivity | - | - |
SUBLIVAC FIX phleum prat. | Phase 2 | Allergic Rhinitis | - | - |
Grass MATAMPL | Phase 2 | Type I Hypersensitivity | - | - |
Tree MATA MPL | Phase 2 | Type I Hypersensitivity | - | - |
Frequently asked questions
What is in Allergy Therapeutics plc's drug pipeline?→
CatalystAlert tracks 15 drug candidates in Allergy Therapeutics plc's (AGY.L) pipeline across Phase 3, Phase 2. Its lead program is Ragweed MATA MPL (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Allergy Therapeutics plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Allergy Therapeutics plc (AGY.L) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AGY.L biotech catalysts?→
Add AGY.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Allergy Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.